276 related articles for article (PubMed ID: 33407304)
1. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
[TBL] [Abstract][Full Text] [Related]
2. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
[TBL] [Abstract][Full Text] [Related]
3. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
6. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
[TBL] [Abstract][Full Text] [Related]
8. [Treatment-related Skin Toxicity Caused by Programmed Death-1 Inhibitor Nivolumab:
A Case Report].
Gao L; Yu Y; Lu S
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):250-254. PubMed ID: 31014445
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
[TBL] [Abstract][Full Text] [Related]
10. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
11. Case 286: Sarcoidlike Granulomatosis and Lymphadenopathy-Thoracic Manifestations of Nivolumab Drug Toxicity.
Chiang J; Hebroni F; Bedayat A; Pourzand L
Radiology; 2021 Feb; 298(2):471-475. PubMed ID: 33493088
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
13. An uncommon presentation of eosinophilic granulomatosis with polyangiitis: a case report.
Taormina G; Andolina G; Banco MA; Costanza-Gaglio EJ; Bonura A; Buscemi S
J Med Case Rep; 2014 Jun; 8():190. PubMed ID: 24928069
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
[TBL] [Abstract][Full Text] [Related]
15. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy.
Domblides C; Gross-Goupil M; Ravaud A; Poullenot F; Daste A
Immunotherapy; 2021 Jun; 13(9):741-744. PubMed ID: 33906378
[TBL] [Abstract][Full Text] [Related]
16. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
Abushalha K; Abulaimoun S; Silberstein PT
Immunotherapy; 2020 Jun; 12(9):625-628. PubMed ID: 32418490
[No Abstract] [Full Text] [Related]
17. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
[TBL] [Abstract][Full Text] [Related]
18. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
19. Relapsing polychondritis after treatment with PD-1 blockade.
Ogimoto T; Yoshida H; Mizuta M; Hirai T
Invest New Drugs; 2022 Apr; 40(2):389-391. PubMed ID: 34562229
[TBL] [Abstract][Full Text] [Related]
20. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]